Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 2

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 2
---
 to buy these securities, in any state where the offer or sale of these securities is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED [●], 2025

PRELIMINARY PROSPECTUS

IMUNON, INC.

UP TO [●] SHARES OF COMMON STOCK

UP TO [●] COMMON WARRANTS TO PURCHASE [●] SHARES OF COMMON STOCK

UP TO [●] PRE-FUNDED WARRANTS TO PURCHASE UP TO [●] SHARES OF COMMON STOCK

UP TO [●] SHARES OF COMMON STOCK UNDERLYING SUCH COMMON WARRANTS

UP TO [●] SHARES OF COMMON STOCK UNDERLYING SUCH PRE-FUNDED WARRANTS</div>

We are offering on a reasonable best-efforts basis up to [●] shares of our common stock, par value $0.01 per share (“ Common Stock”), together with warrants to purchase up to [●] shares of our Common Stock based on an assumed public offering price of $[●] per share of Common Stock and accompanying warrant, which was the closing price of our Common Stock on the Nasdaq Stock Market (“ Nasdaq”) on [●], 2025. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock. The shares of Common Stock and common warrants are immediately separable and will be issued separately in this offering but must be purchased together in this offering. Each common warrant will have an exercise price per share of $[●] and will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants (the “ Warrant Stockholder Approval”); provided however, if (i) the offering is deemed a public offering or (ii) the Pricing Conditions (as defined below) are met, Warrant Stockholder Approval will not be required and the common warrant will be exercisable upon issuance (the “ Initial Exercise Date”). As used herein “ Pricing Conditions” means that the combined public offering price per share of Common Stock and accompanying common warrants is such that the Warrant Stockholder Approval is not required under the rules of Nasdaq because either (i) the offering is an at-the-market offering under Nasdaq rules and such price equals or exceeds the sum of (a) the applicable “Minimum Price” per share under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of Common Stock underlying